Contact
searchSearch
HMP Global
Login

News

News
Circulating Tumor DNA-Guided Adjuvant Atezolizumab Significantly Improves Survival Otucomes in Bladder Cancer
10/20/2025
Stephanie Holland
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by...
10/20/2025
Oncology
News
Disitamab Vedotin Plus Toripalimab Doubles Survival vs Chemotherapy in HER2-Expressing Metastatic Urothelial Carcinoma
10/19/2025
Janelle Bradley
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with...
10/19/2025
Oncology
News
Disitamab Vedotin Plus Toripalimab Doubles Survival vs Chemotherapy in HER2-Expressing Metastatic Urothelial Carcinoma
10/19/2025
Janelle Bradley
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with...
10/19/2025
Oncology
Nicholas James, MD, PhD
Videos
Clinical Impact of Upfront Multiparametric MRI on Staging Accuracy and Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Nicholas James, MD
Nicholas James, MD, PhD, discusses results from the BladderPath trial comparing traditional TURBT-based staging with a multiparametric MRI–guided pathway staging system for suspected muscle-invasive bladder cancer.
Nicholas James, MD, PhD, discusses results from the BladderPath trial comparing traditional TURBT-based staging with a multiparametric MRI–guided pathway staging system for suspected muscle-invasive bladder cancer.
Nicholas James, MD, PhD,...
10/19/2025
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Significantly Improves Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3...
10/19/2025
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Significantly Improves Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3...
10/19/2025
Oncology
News
Cabozantinib Plus Atezolizumab for Patients With Advanced Urothelial Carcinoma
05/13/2025
Stephanie Holland
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the...
05/13/2025
Oncology
Felix Guerrero-Ramos, MD, PhD
Conference Coverage
TAR-200 for BCG-Unresponsive, Papillary-Only High-Risk Non-Muscle Invasive Bladder Cancer
04/28/2025
Felix Guerrero-Ramos, MD, PhD
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD...
04/28/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use